Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB</title><author><name sortKey="Minig, Lucas" sort="Minig, Lucas" uniqKey="Minig L" first="Lucas" last="Minig">Lucas Minig</name></author><author><name sortKey="Patrono, Maria Guadalupe" sort="Patrono, Maria Guadalupe" uniqKey="Patrono M" first="María Guadalupe" last="Patrono">María Guadalupe Patrono</name></author><author><name sortKey="Romero, Nuria" sort="Romero, Nuria" uniqKey="Romero N" first="Nuria" last="Romero">Nuria Romero</name></author><author><name sortKey="Rodriguez Moreno, Juan Francisco" sort="Rodriguez Moreno, Juan Francisco" uniqKey="Rodriguez Moreno J" first="Juan Francisco" last="Rodríguez Moreno">Juan Francisco Rodríguez Moreno</name></author><author><name sortKey="Garcia Donas, Jesus" sort="Garcia Donas, Jesus" uniqKey="Garcia Donas J" first="Jesús" last="Garcia-Donas">Jesús Garcia-Donas</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24829855</idno><idno type="pmc">4014800</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014800</idno><idno type="RBID">PMC:4014800</idno><idno type="doi">10.5306/wjco.v5.i2.86</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">004886</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004886</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB</title><author><name sortKey="Minig, Lucas" sort="Minig, Lucas" uniqKey="Minig L" first="Lucas" last="Minig">Lucas Minig</name></author><author><name sortKey="Patrono, Maria Guadalupe" sort="Patrono, Maria Guadalupe" uniqKey="Patrono M" first="María Guadalupe" last="Patrono">María Guadalupe Patrono</name></author><author><name sortKey="Romero, Nuria" sort="Romero, Nuria" uniqKey="Romero N" first="Nuria" last="Romero">Nuria Romero</name></author><author><name sortKey="Rodriguez Moreno, Juan Francisco" sort="Rodriguez Moreno, Juan Francisco" uniqKey="Rodriguez Moreno J" first="Juan Francisco" last="Rodríguez Moreno">Juan Francisco Rodríguez Moreno</name></author><author><name sortKey="Garcia Donas, Jesus" sort="Garcia Donas, Jesus" uniqKey="Garcia Donas J" first="Jesús" last="Garcia-Donas">Jesús Garcia-Donas</name></author></analytic><series><title level="j">World Journal of Clinical Oncology</title><idno type="ISSN">2218-4333</idno><idno type="eISSN">2218-4333</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Uterine cervical cancer is the second most common gynecological malignancy. It is estimated that over 35% of tumors are diagnosed at locally advanced disease, stage IB2-IIB with an estimated 5-year overall survival of 60%. During the last decades, the initial treatment for these women has been debated and largely varies through different countries. Thus, radical concurrent chemoradiation is the standard of care in United Sated and Canada, and neoadjuvant chemotherapy followed by radical surgery is the first line of treatment in some institutions of Europe, Asia and Latin America. Until today, there is no evidence of which strategy is better over the other. This article describe the evidence as well as the advantages and disadvantages of the main strategies of treatment for women affected by uterine cervical cancer stage IB2-IIB.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">World J Clin Oncol</journal-id><journal-id journal-id-type="publisher-id">WJCO</journal-id><journal-title-group><journal-title>World Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">2218-4333</issn><issn pub-type="epub">2218-4333</issn><publisher><publisher-name>Baishideng Publishing Group Co., Limited</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24829855</article-id><article-id pub-id-type="pmc">4014800</article-id><article-id pub-id-type="other">jWJCO.v5.i2.pg86</article-id><article-id pub-id-type="doi">10.5306/wjco.v5.i2.86</article-id><article-categories><subj-group subj-group-type="heading"><subject>Topic Highlight</subject></subj-group></article-categories><title-group><article-title>Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Minig</surname><given-names>Lucas</given-names></name></contrib><contrib contrib-type="author"><name><surname>Patrono</surname><given-names>María Guadalupe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Romero</surname><given-names>Nuria</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rodríguez Moreno</surname><given-names>Juan Francisco</given-names></name></contrib><contrib contrib-type="author"><name><surname>Garcia-Donas</surname><given-names>Jesús</given-names></name></contrib><aff>Lucas Minig, María Guadalupe Patrono, Gynecologic Oncology Program, Clara Campal Comprehensive Cancer Center, HM Hospitales, 28050 Madrid, Spain</aff><aff>Nuria Romero, Juan Francisco Rodríguez Moreno, Jesús Garcia-Donas, Gynecologic Oncology Program, Medical Oncology Department, Clara Campal Comprehensive Cancer Center, HM Hospitales, 28050 Madrid, Spain</aff></contrib-group><author-notes><fn><p>Author contributions: Minig L, Patrono MG and Romero N performed the literature review and wrote the manuscript; Minig L, Rodríguez Moreno JF and Garcia-Donas J revised the manuscript.</p><p>Correspondence to: Lucas Minig, MD, PhD, Gynecology Oncology Program, Clara Campal Comprehensive Cancer Center, HM Hospitales, Calle Oña 10, 28050 Madrid, Spain. <email>lucasminig@yahoo.com</email></p><p>Telephone: +34-61-6952439 Fax: +34-91-2110119</p></fn></author-notes><pub-date pub-type="ppub"><day>10</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>5</month><year>2014</year></pub-date><volume>5</volume><issue>2</issue><fpage>86</fpage><lpage>92</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2013</year></date><date date-type="rev-recd"><day>22</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>©2014 Baishideng Publishing Group Co., Limited. All rights reserved.</copyright-statement><copyright-year>2014</copyright-year></permissions><abstract><p>Uterine cervical cancer is the second most common gynecological malignancy. It is estimated that over 35% of tumors are diagnosed at locally advanced disease, stage IB2-IIB with an estimated 5-year overall survival of 60%. During the last decades, the initial treatment for these women has been debated and largely varies through different countries. Thus, radical concurrent chemoradiation is the standard of care in United Sated and Canada, and neoadjuvant chemotherapy followed by radical surgery is the first line of treatment in some institutions of Europe, Asia and Latin America. Until today, there is no evidence of which strategy is better over the other. This article describe the evidence as well as the advantages and disadvantages of the main strategies of treatment for women affected by uterine cervical cancer stage IB2-IIB.</p></abstract><kwd-group><kwd>Locally advanced cervical cancer</kwd><kwd>Federation of Gynecology and Obstetrics stage IB2-IIB</kwd><kwd>Radiotherapy</kwd><kwd>Neoajuvant chemotherapy</kwd><kwd>Radical hysterectomy</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004886 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 004886 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |